Skip to Content

Here’s what we could do with the first-ever cloned monkeys

January 24, 2018

Chinese scientists say they’ve copied monkeys using cloning for the first time. The animals join a long list of cloned mammals that began with Dolly the sheep in 1996.

The monkeys: Scientists have cloned four long-tailed macaques in total. Two died from respiratory failure, though—a problem already seen with cloned pigs and cows. The survivors, pictured above, are named Zhong Zhong and Hua Hua.

So, are humans next? We don’t think so. It’s far too risky and controversial—however tempting the idea of cloning a lost loved one might be.

More realistic goals: Instead, it’s likely that researchers will try to create cloned monkeys harboring mutations that cause specific human disease, like muscular dystrophy or autism. That could give us a way to try to treat those diseases in animals similar to us.

Deep Dive


This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

How do strong muscles keep your brain healthy?

There’s a robust molecular language being spoken between your muscles and your brain.

The quest to show that biological sex matters in the immune system

A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.